Quantcast

Industry news that matters to you.  Learn more

Clusterin Not a Potential Early Biomarker for Alzheimer’s Disease Development

Reading time: 2 minutes

According to a recent study published in the Journal of the American Medical Association, plasma clusterin levels are significantly associated with prevalence and severity of Alzheimer’s disease (AD), but not with incidence.

Using data from the Rotterdam Study, researchers at Erasmus MC University Medical Center, Rotterdam, the Netherlands, and colleagues examined the associations between plasma levels of clusterin and the prevalence, severity and risk of AD. Plasma clusterin levels were measured at baseline in 60 individuals with prevalent AD, 156 participants diagnosed with AD during follow-up (average 7.2 years) and a random sub-group of 926 individuals. The main outcome measures were prevalent AD, severity of AD (measured by the Mini-Mental State Examination (MMSE) score), and the risk of developing AD during follow-up.

The investigators found that the likelihood of prevalent AD increased with increasing plasma levels of clusterin. Increased clusterin levels in patients with AD were associated with more severe disease. Plasma clusterin levels were not found to be related to the risk of incident AD within 3 years of baseline or during total follow-up.

The authors conclude by writing:

Our data from the general population show that increased plasma clusterin levels are associated with prevalent AD and are higher in more severe cases of AD. However, increased levels of clusterin do not precede development of AD and therefore are not a potential early marker of subclinical disease.

Study: Plasma Clusterin and the Risk of Alzheimer Disease

Source: JAMA News